Theravance Biopharma Inc (TBPH) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Theravance Biopharma Inc (US:TBPH), currently being evaluated. In 2025, Theravance Biopharma Inc generated $107.46 Million in revenue and $238.50 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Theravance Biopharma Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $107.46 Million
- Free Cash Flow (2025): $238.50 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.